Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Next Previous
Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Alternative Names: Men Quad TT; MenACYW conjugate vaccine; Meninge ACTW conj - Sanofi; Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; MenQuadfi; Quadrivalent Meningococcal Conjugate Vaccine; TetraMen-T

Latest Information Update: 17 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group A infections
  • Registered Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Phase III Meningococcal infections

Most Recent Events

  • 15 Nov 2025 Sanofi completed the phase III trial in Meningococcal group A infections (In infants, Prevention) in South Africa and India (IM) (NCT05794230)
  • 14 Nov 2025 sanofi-aventis completes a phase III trial in Meningococcal group A infections, Meningococcal group C infections, Meningococcal group Y infections and Meningococcal group W-135 infections (Prevention, In infants) in Romania, Poland, Germany, Denmark, Finland, Czech Republic (IM) (NCT06284915)
  • 26 Sep 2025 Phase-III clinical trials in Meningococcal infections (In children, In adolescents, Prevention, In volunteers) in China (IM) (NCT07135986)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top